What records are connected here?
- Evidence lanes
- 2
- Source years
- 2
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials4,5Evidence: Smaller human trialsMetabolic and weight
Eloralintide is a synthetic peptide that activates the amylin receptor, recorded in FDA’s substance registry and in development for weight management.4,5 In a randomized, placebo-controlled Phase 2 trial of 263 adults with obesity or overweight, average weight change after 48 weeks ranged from 9% to 20% lower across eloralintide groups, compared with 0.4% lower on placebo.5 No FDA approval is reported in the sources reviewed here, and eloralintide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.4,8
| What it is | A synthetic, selective amylin receptor agonist peptide, also recorded as AMY-1176 in FDA’s substance registry.4,5 |
|---|---|
| FDA status | Not FDA-approved. None of the sources reviewed here reports an approval of eloralintide.4,5 |
| Human evidence | A 48-week randomized, double-blind, placebo-controlled Phase 2 trial in 263 adults with obesity or overweight, published in 2025.5 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Eloralintide is a synthetic peptide recorded in FDA’s substance registry as eloralintide and AMY-1176.4
The 2025 trial report describes it as a novel, selective amylin receptor agonist in development for weight management; the trial was funded by Eli Lilly.5
It is designed to act selectively on the receptor for the hormone amylin. The trial authors place it among amylin-based therapies emerging as obesity medicines.5
The Phase 2 trial randomized 263 adults with obesity, or with overweight and a weight-related condition, and without type 2 diabetes, to one of several eloralintide groups or placebo for 48 weeks.5
Average body weight fell by 9% to 20% across eloralintide groups, compared with 0.4% on placebo. Nausea and fatigue were the most common adverse events and were more frequent in some eloralintide groups than with placebo.5
ClinicalTrials.gov lists several Phase 3 trials of eloralintide as recruiting in 2026 registry records, including trials in obesity or overweight (NCT07321886), in osteoarthritis with overweight or obesity (NCT07353931) and in obstructive sleep apnea with obesity (NCT07369011).1,2,3
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of eloralintide by FDA.4,5
Eloralintide remains in clinical trials: Phase 3 registrations such as NCT07321886 are listed as recruiting in their 2026 records.1
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list eloralintide.6
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Eloralintide is not among them.7,8
Whether the weight loss seen in a 263-person Phase 2 trial holds in larger, longer trials, and how it compares with other obesity medicines, which the trial did not test.5
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Eloralintide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Eloralintide are a bounded selection, not every registration or paper about Eloralintide. For the years before Eloralintide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Eloralintide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Eloralintide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 2 trial of 263 adults, weight fell by 9% to 20% across eloralintide groups over 48 weeks. Eloralintide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 2 trial of 263 adults, weight fell by 9% to 20% across eloralintide groups over 48 weeks. Eloralintide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 13, 2026
ClinicalTrials.gov record NCT07935304↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07935304↗Source date November 13, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07282600↗Source date November 4, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07353931↗Source date November 4, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
19 of 19 selected trial records include at least one phase value; 19 of 19 include a status value in the retained structured contract.
1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT06230523 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT06916065 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide.
1 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span November 19, 2025 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07282600 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07353931 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07369011 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07392190 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07900633 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07215559 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-09, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07589608 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07808060 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07701083 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07321886 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07738614 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-20, and PeptideScanner's reviewed identity mapping was eloralintide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
The Lancet · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026